Abu Dhabi and Boehringer Ingelheim team up to advance precision medicine research

Abu Dhabi's Department of Health and German pharmaceutical giant Boehringer Ingelheim have signed a memorandum of understanding to collaborate on precision medicine research. The deal was announced at the BIO International Convention 2026 in San Diego on June 26, with senior officials from both sides present at the signing.

The partnership will use Abu Dhabi's existing genomics infrastructure to study how genetic and population-level factors affect disease development and how patients respond to treatment. Researchers will focus on a wide range of conditions, including cardiovascular disease, diabetes, cancer, rare diseases, neurological disorders, metabolic diseases, fibrotic diseases, eye conditions, and immunological conditions.

The MoU was signed by Dr. Mohamed Al Ameri, Division Director of Genome and Biobank at the Department of Health, and Ghaleb Al Ahdab, Head of Public and Government Affairs UAE and Near East at Boehringer Ingelheim. Her Excellency Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health Abu Dhabi, was also present at the ceremony.

How will it work?

The collaboration will draw on Abu Dhabi's genomics programs and research infrastructure to generate scientific insights that neither organization could easily produce alone. While the MoU sets out the intent to work together, the two sides will now explore specific research opportunities within the agreed focus areas.

The goal is to build a clearer picture of:

• Which genetic factors make certain populations more susceptible to specific diseases
• How those factors vary across Abu Dhabi's population
• How patients with different genetic profiles respond to existing and future treatments

Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health Abu Dhabi, said the collaboration reflects the emirate's commitment to put its genomics capabilities to work. "The knowledge we generate will inform future research, advance personalised healthcare approaches, and contribute to more effective, sustainable health outcomes for Abu Dhabi and the wider region," she said.

Why does it matter?

Precision medicine relies on understanding how individual biology shapes health and disease. That requires large, well-structured datasets and the infrastructure to analyze them. Abu Dhabi has spent years building exactly that, and this deal gives Boehringer Ingelheim access to those resources while giving Abu Dhabi a link to a global drug developer's research pipeline.

For patients, the practical payoff would be treatments better matched to their biology rather than one-size-fits-all approaches. That matters especially in a region where some genetic variants common in Middle Eastern populations are underrepresented in global clinical research.

Ousama Alhaj, General Manager and Head of Human Pharma for Near East and UAE at Boehringer Ingelheim, said the partnership reflects a shared focus on understanding disease prevalence and addressing unmet medical needs. "Abu Dhabi has strategically invested in many of the critical enablers of precision medicine, from large-scale genomics programs and advanced research infrastructure to a clear national vision for leading the future of healthcare," he said.

The context

Abu Dhabi has made genomics a central part of its health strategy over the past decade. The emirate runs large-scale population health programs, including the Abu Dhabi Genome Program, which aims to sequence the genomes of UAE nationals and long-term residents to build a reference database for the region.

Boehringer Ingelheim is one of the world's largest privately held pharmaceutical companies, with a strong research focus in several of the disease areas covered by this partnership, particularly cardiovascular disease, diabetes, and fibrotic conditions. Signing deals at BIO International is a well-established route for pharma companies to formalize research relationships, and this agreement fits a broader industry trend of large drugmakers partnering with regional health authorities to access diverse population data.

The deal also reflects growing competition among Gulf states to attract life sciences investment and establish themselves as research hubs, with Saudi Arabia, Qatar, and the UAE all pursuing similar strategies.